|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0100 CAD | 0.00% |
|
0.00% | -33.33% |
| 05-28 | Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-29 | Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 1.34M 963K 835K 781K 714K 91.98M 1.37M 9.17M 3.59M 46.01M 3.62M 3.54M 153M | P/E 2024 |
-1.31x | P/E 2025 | -4.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.84M 2.04M 1.77M 1.65M 1.51M 195M 2.89M 19.43M 7.6M 97.46M 7.67M 7.5M 325M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
77.22% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -33.33% | ||
| 6 months | -33.33% | ||
| Current year | -33.33% |
| 1 week | 0 |  | 0.01 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.02 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.08 |
| 5 years | 0 | | 0.46 |
| 10 years | 0 | | 4.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Appleby
DFI | Director of Finance/CFO | 50 | 2023-10-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 82 | 2016-12-19 |
David Kideckel
CHM | Chairman | - | 2024-02-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/14/25 | Other | Chairman | 1,380,000 | 1.2929% | ||
| 5/3/24 | Other | Director | 0 | 0% | ||
| 5/3/24 | Option | Director | 500,000 | 0.5718% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | 0.00% | -71.43% | 963K | |
| +2.49% | +9.02% | +34.88% | +107.79% | 103B | |
| +1.30% | +1.98% | +52.63% | +160.19% | 55.55B | |
| +0.34% | 0.00% | +3.85% | +271.25% | 24.05B | |
| -0.18% | -0.71% | -12.53% | -13.66% | 8.31B | |
| +0.61% | +4.34% | -29.81% | -24.87% | 7.7B | |
| -1.35% | -3.61% | -10.86% | -22.80% | 6.79B | |
| -0.24% | +2.83% | +18.99% | +14.71% | 6.19B | |
| -0.73% | -3.49% | -3.26% | +20.53% | 5.06B | |
| +0.40% | -1.55% | -5.23% | -5.41% | 3.73B | |
| Average | +0.26% | +125.89% | +4.87% | +43.63% | 22B | |
| Weighted average by Cap. | +1.48% | +467.82% | +28.50% | +119.09% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -793K -569K -494K -462K -422K -54.36M -807K -5.42M -2.12M -27.19M -2.14M -2.09M -90.71M | -383K -275K -239K -223K -204K -26.27M -390K -2.62M -1.02M -13.14M -1.03M -1.01M -43.84M |
| Net Debt | 1.27M 914K 793K 741K 677K 87.31M 1.3M 8.71M 3.4M 43.67M 3.44M 3.36M 146M | 1.5M 1.08M 934K 873K 798K 103M 1.53M 10.26M 4.01M 51.45M 4.05M 3.96M 172M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-10 | $0.0100 | +100.00% | 255,500 |
| 26-08-06 | $0.005000 | 0.00% | 8,071 |
- Stock Market
- Stocks
- PHRX Stock
Select your edition
All financial news and data tailored to specific country editions
